This Is MS Multiple Sclerosis Community: Knowledge & Support

Study supports long-term safety profile of Betaferon® for Multiple Sclerosis over 16 years



Results from the 16-year follow-up to the pivotal Betaferon® (interferon-beta-1b) trial, published today in the journal Neurology, provide the longest and most complete patient follow-up data and support the long-term safety profile of Betaferon in multiple sclerosis (MS).

Results demonstrated that no new or unexpected adverse events (AEs) emerged with long-term therapy, and the observed treatment-related AEs decreased over time.

"These data confirm that Betaferon has a favorable safety and tolerability profile," said Anthony T. Reder, Professor of Neurology at the University of Chicago and lead study author. "Over the years, healthcare professionals have been able to greatly reduce treatment-related adverse events and increase patients? adherence to Betaferon therapy with dose escalation at initiation of therapy and the routine use of an autoinjector and co-medication with non-steroidal anti-inflammatory drugs (or NSAIDs)."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1766

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis